FCA
ADCT icon

FinTrust Capital Advisors’s ADC Therapeutics ADCT Stock Holding History

FinTrust Capital Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-180
Closed -$6K – 1068
2020
Q3 		$6K Buy
+180
New +$7.79K ﹤0.01% 917

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

FinTrust Capital Advisors's ADCT Position: Q4 2020 in Review

FinTrust Capital Advisors sold out of ADC Therapeutics (ADCT) in Q4 2020, closing a stake of 180 shares — an estimated $6K sold.

FinTrust Capital Advisors first reported a position in ADCT in Q3 2020 and held it in 1 quarter. The position peaked at $6K in Q3 2020. 51 funds tracked by Wall St. Rank hold ADCT as of Q4 2020.

  • FinTrust Capital Advisors reported no remaining ADC Therapeutics position as of Q4 2020 after selling out during the quarter.
  • FinTrust Capital Advisors sold 180 ADC Therapeutics shares in Q4 2020, an estimated $6K.
  • FinTrust Capital Advisors first reported a position in ADC Therapeutics in Q3 2020 and held it in 1 quarter.
  • FinTrust Capital Advisors's ADC Therapeutics position peaked at $6K in Q3 2020.
  • 51 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2020.

Based on FinTrust Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.